Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rectal BBT-401-1S in Ulcerative Colitis
NCT04478825Phase 1Terminated
- Sponsor
- Bridge Biotherapeutics
- Start
- Jun 2021
- Primary completion
- Aug 2021
- Modality
- Small Molecules, Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BBT-401 in ulcerative colitis (UC), sponsored by Bridge Biotherapeutics. Primary endpoint: Endoscopic remission rate at Day 57. Started Jun 2021; status: terminated.
02
Drugs
BBT-401
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT04478825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04478825.